B of A Securities Maintains Underperform on Fate Therapeutics, Raises Price Target to $6

Fate Therapeutics, Inc. +2.62% Post

Fate Therapeutics, Inc.

FATE

3.52

3.52

+2.62%

0.00% Post

B of A Securities analyst Tazeen Ahmad maintains Fate Therapeutics (NASDAQ: FATE) with a Underperform and raises the price target from $2 to $6.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via